Financial Performance - The company's operating revenue for the reporting period was CNY 636,971,276.24, a decrease of 11.78% compared to the previous year[3] - Net profit attributable to shareholders increased by 7.87% to CNY 100,021,632.44, driven by reduced marketing expenses and strict cost control measures[6] - The net profit excluding non-recurring gains and losses rose by 15.93% to CNY 85,543,938.64, primarily due to lower previous year's non-recurring gains[6] - Basic earnings per share decreased by 2.38% to CNY 0.82[5] - The decline in operating revenue was mainly due to significant price reductions of key products entering national procurement[6] Assets and Equity - Total assets at the end of the reporting period were CNY 1,844,554,227.12, reflecting a growth of 2.49% from the beginning of the period[5] - Shareholders' equity attributable to the company increased by 5.09% to CNY 1,555,537,078.34[5] - The net asset value per share attributable to shareholders increased by 5.30% to CNY 12.72[4] - The company's stock capital decreased by 0.24% to CNY 122,288,200[4] Cautionary Notes - The financial data presented is preliminary and has not been audited, cautioning investors about potential risks[8]
星昊医药(430017) - 2024 Q4 - 年度业绩